Axsome Therapeutics AXSM Proceeds From Long Term Lines Of Credit
Proceeds From Long Term Lines Of Credit at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromLongTermLinesOfCredit.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's proceeds from long term lines of credit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's proceeds from long term lines of credit?
- Axsome Therapeutics (AXSM) reported proceeds from long term lines of credit of $70M in Q1 2026.
- What does proceeds from long term lines of credit mean?
- Cash received from borrowing against long-term credit lines.
- How do you interpret proceeds from long term lines of credit?
- An increase indicates reliance on debt financing to support liquidity, while a decrease suggests reduced borrowing or reliance on internal cash flows.
- How does proceeds from long term lines of credit compare across companies?
- Common in clinical-stage biotechs to manage cash runway; peers often show periodic spikes during capital-intensive development phases.